{"id":169565,"date":"2025-07-30T08:56:45","date_gmt":"2025-07-30T12:56:45","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169565"},"modified":"2025-07-30T08:56:45","modified_gmt":"2025-07-30T12:56:45","slug":"ajanta-pharma-ltd-q1-fy26-earnings-results-revenue-up-13-8-net-profit-up-3-7-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/ajanta-pharma-ltd-q1-fy26-earnings-results-revenue-up-13-8-net-profit-up-3-7-yoy\/","title":{"rendered":"Ajanta Pharma Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 13.8%, Net Profit Up 3.7% YoY"},"content":{"rendered":"<p>Ajanta Pharma Limited is a specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company focuses on delivering innovative and affordable medicines across multiple therapeutic segments, strengthening its presence in domestic and international markets.<\/p>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/4cf818b5-e94c-4440-983a-30cdf70e514c.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Q1 FY26 Earnings Summary (Apr\u2013Jun 2025)<\/strong><\/a><\/p>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b91,303 crore, up 13.8% year-on-year (YoY) from \u20b91,145 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b9997 crore, up 17.29% YoY from \u20b9850 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9255 crore, up 3.66% from \u20b9246 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b920.44, up 3.86% from \u20b919.68 YoY.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169566\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<p><strong>Operational &amp; Strategic Update<\/strong><\/p>\n<ul>\n<li><strong>Robust Revenue Growth:<\/strong> The healthy increase in revenue was driven by strong demand across key specialty formulations and strategic expansion in both emerging and regulated international markets.<\/li>\n<li><strong>Expense Growth:<\/strong> Expenses rose at a higher rate compared to revenue, mainly due to increased investments in R&amp;D, marketing, regulatory compliance, and scaling operational capacities to support growth.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/4cf818b5-e94c-4440-983a-30cdf70e514c.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Profitability<\/strong><\/a><strong>:<\/strong> Despite a relatively smaller rise in net profit compared to revenue, Ajanta Pharma maintained steady profitability with improved EPS, reflecting operational resilience amid margin pressures.<\/li>\n<li><strong>Product &amp; Market Focus:<\/strong> Continued emphasis on specialty therapeutic segments such as dermatology, ophthalmology, and cardio-metabolic diseases, supported by new product launches and increased market penetration.<\/li>\n<li><strong>Research &amp; Development:<\/strong> Ongoing focus on innovation and pipeline development to enhance the product portfolio and sustain competitive advantage.<\/li>\n<li><strong>Geographic Expansion:<\/strong> Strengthened foothold in overseas markets including Africa, Asia, and Latin America, leveraging regulatory approvals and partnerships.<\/li>\n<li><strong>Sustainability &amp; Compliance:<\/strong> Commitment to quality, regulatory compliance, and sustainable manufacturing practices remains a core priority.<\/li>\n<\/ul>\n<p><strong>Corporate Developments<\/strong><\/p>\n<p>Ajanta Pharma\u2019s <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/4cf818b5-e94c-4440-983a-30cdf70e514c.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26 results<\/a> indicate strong topline growth supported by product innovation and market expansion, though profitability experienced moderate pressure due to higher expenses. The company\u2019s strategic investments in R&amp;D and overseas operations position it well for future growth.<\/p>\n<p><strong>Looking Ahead<\/strong><\/p>\n<p>With a focus on driving specialty product innovation, expanding global reach, and optimizing operational efficiencies, Ajanta Pharma Ltd is poised to sustain growth momentum and enhance shareholder value in FY26 and beyond.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma Limited is a specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company focuses on delivering innovative and affordable medicines across multiple therapeutic segments, strengthening its presence in domestic and international markets. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: \u20b91,303 crore, up 13.8% year-on-year (YoY) [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169565","post","type-post","status-publish","format-standard","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":145168,"url":"https:\/\/alphastreet.com\/india\/earnings-ajanta-pharma-ltd-nse-ajantapharma-q4fy23-results-out-total-income-rises-2-1-yoy\/","url_meta":{"origin":169565,"position":0},"title":"Earnings | Ajanta Pharma Ltd. (NSE: AJANTAPHARMA): Q4FY23 Results Out; Total Income rises 2.1% YoY.","author":"Divyansh_Kasana","date":"May 5, 2023","format":false,"excerpt":"Ajanta Pharma is a leading Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of high-quality specialty pharmaceutical finished dosages. Founded in 1973, the company has a strong focus on research and development and has invested heavily in building state-of-the-art facilities and advanced technologies. Ajanta Pharma has a\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-21.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169565,"position":1},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172355,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":169565,"position":2},"title":"Orchid Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 12, 2025","format":false,"excerpt":"Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b9193.52 crore, down 13.1% YoY but up 11.9% QoQ EBITDA: \u20b9-1.48 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Orchid Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":169565,"position":3},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169833,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy\/","url_meta":{"origin":169565,"position":4},"title":"Aurobindo Pharma Ltd Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets. Financial Highlights In Q1 FY26, Aurobindo Pharma reported revenue\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170207,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":169565,"position":5},"title":"Astrazeneca Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 15, 2025","format":false,"excerpt":"AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25. Total Expenses: \u20b9726 crore, up 20.40% YoY from \u20b9603 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ASTRAZEN Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169565"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169565\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}